The Changing Drug Culture: Use and Misuse of Cognition-Enhancing Drugs.
Study Design
- 研究类型
- Review
- 研究人群
- children
- 干预措施
- The Changing Drug Culture: Use and Misuse of Cognition-Enhancing Drugs. None
- 对照组
- None
- 主要结局
- None
- 效应方向
- Positive
- 偏倚风险
- Unclear
Abstract
There has been an increase in diagnoses of attention-deficit/hyperactivity disorder (ADHD), with approximately 9% of American children now diagnosed, and a concomitant increase in the use of stimulants (eg, amphetamines, methylphenidate) to manage ADHD. Nonstimulant drugs (eg, atomoxetine, guanfacine, clonidine) also are used, but most patients are treated with stimulants. All of these drugs are effective for management of ADHD, and, overall, use in childhood does not seem to increase the risk of substance abuse later in life. However, widespread use has resulted in prescription stimulants being diverted for nonmedical uses, particularly by high school and college students seeking cognitive enhancement for improved academic performance. Studies of ADHD drugs for improving cognition in patients without ADHD have mixed results, and any improvements appear to be modest and short-term. Other substances also are used for cognitive enhancement. Drugs for Alzheimer disease are being used for mild cognitive impairment, though there is no evidence that they are effective. Creatine may have mild cognition-enhancing properties, but study results often are confounded by the addition of exercise, which by itself is thought to improve cognition. There is no evidence that other supplements, such as vitamins and omega-3 fatty acids, improve cognitive function.
简要概述
Overall, use in childhood does not seem to increase the risk of substance abuse later in life, but widespread use has resulted in prescription stimulants being diverted for nonmedical uses, particularly by high school and college students seeking cognitive enhancement for improved academic performance.
Used In Evidence Reviews
Similar Papers
Pharmacological research · 1999
Health benefits of docosahexaenoic acid (DHA).
Circulation · 2010
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Contemporary clinical trials · 2012
The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
Journal of clinical hypertension (Greenwich, Conn.) · 2011
Role of mercury toxicity in hypertension, cardiovascular disease, and stroke.
Progress in neuro-psychopharmacology & biological psychiatry · 2008
The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
The Cochrane database of systematic reviews · 2007